Clinical Trial Update: A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen [Phase 3]

View source ↗

Summary

A Phase 3 safety trial of nivolumab in advanced or metastatic non-small cell lung cancer after prior chemotherapy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 3 | Status: COMPLETED | Results posted: 2022-10-27